Solventum (SOLV) Investor Day 2025 summary

Strategic transformation and business progress

• Completed first year as an independent company, implementing a three-phase transformation focused on culture, strategy, and portfolio optimization, reversing six years of volume declines and seven quarters of negative growth post-separation from 3M.

• Overhauled leadership and talent, with 85% new executive team and significant changes at VP and critical transformation roles, fostering a mission-driven culture focused on autonomy and accountability.

• Decentralized structure and specialized commercial organization to drive accountability, speed, and focus on growth drivers, with diversified business across MedSurg (64% of 2024 revenue), Dental Solutions (18%), and Health Information Systems (18%).

• Divested Purification and Filtration business for $4.1B, enabling a 50% reduction in debt, increased financial flexibility, and acceleration of M&A.

• Enhanced innovation process, raising the vitality index from 2% to 10% by 2027-2028 through pipeline rationalization and targeted R&D.

Growth strategy and operational focus

• 80% of revenue growth is expected from five key drivers: Negative Pressure Wound Therapy, IV Site Management, Sterilization Assurance, Core Restoratives, and Revenue Cycle Management.

• Growth will be driven by commercial excellence, innovation, and targeted M&A, with a focus on both organic and inorganic opportunities.

• Each business segment has a phased approach to market leadership, emphasizing talent, commercial productivity, and innovation.

• Supply chain initiatives include network simplification, automation, supplier excellence, regional manufacturing, and inventory optimization, reducing back orders by 33% in the past year.

• The Solventum Way restructuring program is delivering $120M in annual savings, offsetting public company stand-alone costs and supporting growth investments.

Financial guidance and value creation targets

• 2025 guidance: 1%-2% organic sales growth (+1.5%-2.5% excluding SKU exits), $5.45-$5.65 adjusted EPS, $450M-$550M free cash flow, with separation costs peaking in 2025 and declining thereafter.

• Long-range plan targets by 2028: 4%-5% organic sales growth, 23%-25% operating margins (25%-27% excluding 3M COGS impact), 10% EPS CAGR, and 80%+ free cash flow conversion.

• Margin expansion plan incorporates 200 bps headwind from 3M supply agreements, offset by programmatic savings, supply chain optimization, and portfolio mix.

• Purification and Filtration divestiture expected to be neutral to 2025 EPS, accretive by $0.15-$0.20 annually thereafter, and add ~200 bps to gross margin and ~100 bps to operating margin.

• Capital allocation priorities: debt paydown, growth investments (R&D, capex), programmatic M&A, with future consideration for share repurchases/dividends, and focus on maintaining investment-grade credit rating and attractive ROIC.